Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2218

1.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

2.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

3.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

4.

Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.

Stone NJ, Bilek S, Rosenbaum S.

Am J Cardiol. 2005 Aug 22;96(4A):53E-59E. Review.

PMID:
16098845
5.
6.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
7.

Treatment of high-risk older persons with lipid-lowering drug therapy.

Aronow WS.

Am J Ther. 2008 Mar-Apr;15(2):102-7. doi: 10.1097/MJT.0b013e31802b5aa4. Review.

PMID:
18356628
8.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035
9.
11.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
12.

Rising to the challenge of treating high-risk patients.

Guthrie RM.

Am J Manag Care. 2006 Oct;12(11 Suppl):S318-24.

13.
14.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
15.

[A new approach to the treatment of dyslipidemia].

Kevelaitiene S, Slapikas R.

Medicina (Kaunas). 2008;44(5):407-13. Review. Lithuanian.

17.
18.

Combination therapy for combined dyslipidemia.

Xydakis AM, Ballantyne CM.

Am J Cardiol. 2002 Nov 20;90(10B):21K-29K. Review.

PMID:
12467937
19.

Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease.

Aronow WS, Frishman WH.

Cardiol Rev. 2010 May-Jun;18(3):132-40. doi: 10.1097/CRD.0b013e3181c29571. Review.

PMID:
20395698
20.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192

Supplemental Content

Support Center